Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Vectibix
| Field | Information |
|---|---|
| Medication Name | Vectibix |
| Generic Name | Panitumumab |
| Boxed/Label Warning | Severe infusion reactions and dermatologic toxicities |
| Purpose | Treatment of metastatic colorectal cancer with wild-type KRAS (RAS) |
| Mechanism of Action | Monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), blocking its activation. |
| Dosage Forms | Intravenous solution |
| Available Strengths | 20 mg/mL |
| Dosage Frequency | Every 2 weeks, as directed by a healthcare provider |
| Common Side Effects | Skin rash, fatigue, nausea, diarrhea, hypomagnesemia, infusion reactions |
| Serious Side Effects | Severe skin reactions (e.g., Stevens-Johnson syndrome), infusion reactions (e.g., anaphylaxis), pulmonary fibrosis, electrolyte imbalances, dermatologic toxicity |
| Drug Interactions | Avoid use with other EGFR inhibitors |
| Important Notes | Administered by intravenous infusion. Monitor for skin reactions and electrolyte imbalances. Consult a healthcare provider for any concerns. Premedication may be needed to reduce infusion reactions. |
| Storage | Store refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. |
| Missed Dose | Contact your healthcare provider immediately to reschedule your appointment. |
| Alternatives | Cetuximab, Bevacizumab, Zaltrap, Erbitux |
Vectibix Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Cetuximab (Erbitux) | EGFR inhibitor | Another monoclonal antibody targeting EGFR. Must also have wild-type RAS. |
| Bevacizumab (Avastin) | VEGF inhibitor | Targets vascular endothelial growth factor, inhibiting angiogenesis. |
| Ziv-aflibercept (Zaltrap) | VEGF inhibitor | A recombinant fusion protein that binds VEGF. |
| Chemotherapy Regimens (e.g., FOLFOX, FOLFIRI) | Various | Combination chemotherapy regimens used in colorectal cancer treatment. |
Vectibix Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Skin rash | Severe skin reactions (Stevens-Johnson syndrome) |
| Fatigue | Infusion reactions (anaphylaxis) |
| Nausea | Pulmonary fibrosis |
| Diarrhea | Electrolyte imbalances (hypomagnesemia) |
| Hypomagnesemia | Dermatologic toxicity |
| Infusion reactions | Infections |
Vectibix Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Metastatic Colorectal Cancer (wild-type RAS) | 6 mg/kg | 6 mg/kg every 2 weeks | Administered as an intravenous infusion. Premedication may be needed to reduce infusion reactions. |
Vectibix Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $300 – $1000 |
| Without Insurance (U.S.) | $5700 – $7080 |
| From Canada | $4045 |
